Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.60 |
| ▸ | RXRA | P19793 | 6/20 | 0.60 |
| ▸ | RXRB | P28702 | 6/20 | 0.60 |
| ▸ | RXRG | P48443 | 2/20 | 0.60 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.58 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.48 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27754142 | 0.88 | S1PR4 (0.47) | PLA2G4BRXRARXRBRXRGNR4A2 | |
| SCHEMBL2957643 | 0.86 | MAPT (0.55) | PLA2G4BMAOBMAOANPC1POLB | |
| SCHEMBL2957648 | 0.85 | MAOB (0.51) | PLA2G4BRXRARXRBRXRGMRGPRX4 | |
| SCHEMBL28571002 | 0.83 | MEN1 (0.50) | MAOBMAOANPC1POLBRAB9A | |
| SCHEMBL2967979 | 0.83 | MAPT (0.51) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15282049 | 0.81 | PLA2G4B (0.87) | PLA2G4BRXRARXRBNR4A2MAOB | |
| SCHEMBL2957654 | 0.81 | MAPT (0.54) | MAOBMAOAPOLB | |
| SCHEMBL11265699 | 0.80 | MEN1 (0.70) | PLA2G4BNR4A2MAOBMAOARAB9A | |
| SCHEMBL16396254 | 0.79 | RAB9A (0.60) | PLA2G4BMRGPRX4MAOBMAOANPC1 | |
| SCHEMBL23978217 | 0.77 | MRGPRX4 (0.60) | PLA2G4BRXRARXRBRXRGNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338605-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100256139-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-10-07 | — | — | US | disclosed |
| EP-1979349-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2010-07-28 | — | — | EP | disclosed |
| US-7763731-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2010-07-27 | — | — | US | disclosed |
| CN-101384592-A | Antiviral compounds | ABBOTT LAB (US) | 2009-03-11 | — | — | CN | disclosed |
| EP-1979349-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007076035-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | PLA2G4B 4315/4885RXRA 3052/4885RXRB 3163/4885 |
| US-20100256139-A1 | Anti-Viral Compounds | HAVCR2, MAVS, EIF2AK2 | PLA2G4B 4315/4885RXRA 3052/4885RXRB 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.